MAIA Biotechnology, Inc. (MAIA) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, MAIA Biotechnology reported revenue of $0. Net income was -$22.4M, or -$0.70 per diluted share. Operating activities generated -$18.8M of cash. At fiscal year end, MAIA Biotechnology held $9.7M in total assets against $7.3M in total liabilities, including $0 of cash and equivalents.
Open the full interactive MAIA Biotechnology financials → Quarterly statements, key ratios, valuation history and price charts.
MAIA Biotechnology Key Stats
| Share Price | $1.16 |
|---|---|
| Market Cap | $70.5M |
| 52-Week Range | $0.87 – $2.95 |
| Shares Outstanding | 60.8 million (basic, 2026 Q2) |
MAIA Biotechnology Income Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Operating Income | -$16.2M | -$20.2M | -$17.0M | -$24.3M |
| Pre-Tax Income | -$15.8M | -$19.8M | -$23.3M | -$22.4M |
| Income Tax | -$30,721 | -$27,095 | -$45,344 | $2,000 |
| Net Income | -$15.8M | -$19.8M | -$23.3M | -$22.4M |
| Diluted EPS | -$1.75 | -$1.49 | -$1.05 | -$0.70 |
MAIA Biotechnology Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$8.9M | -$3.6M | -$6.4M | -$7.9M |
| Diluted EPS | -$0.27 | -$0.11 | -$0.14 | -$0.13 |
MAIA Biotechnology Balance Sheet
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Cash & Equivalents | $0 | $0 | $0 | $0 |
| Current Assets | $11.8M | $7.6M | $10.2M | $9.7M |
| Total Assets | $12.0M | $7.6M | $10.2M | $9.7M |
| Current Liabilities | $3.3M | $4.9M | $3.8M | $5.8M |
| Total Liabilities | $3.5M | $7.1M | $6.5M | $7.3M |
| Shareholders' Equity | $8.5M | $477,511 | $3.6M | $2.4M |
MAIA Biotechnology Cash Flow Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Cash From Operations | -$11.7M | -$13.1M | -$15.7M | -$18.8M |
| Cash From Financing | $12.0M | $9.3M | $18.2M | $17.9M |
Figures from MAIA Biotechnology's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full MAIA Biotechnology financials page for every line item.
MAIA Biotechnology Company Profile
| Ticker | MAIA |
|---|---|
| Exchange | NYSE |
| Industry | Pharmaceutical Preparations |
| Headquarters | Chicago, Illinois |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001878313 |
Frequently Asked Questions
What was MAIA Biotechnology's revenue in fiscal 2025?
MAIA Biotechnology (MAIA) reported revenue of $0 for fiscal 2025.
What is MAIA Biotechnology's annual revenue history?
MAIA Biotechnology's annual revenue by fiscal year: 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was MAIA Biotechnology's net income in fiscal 2025?
MAIA Biotechnology reported net income of -$22.4M for fiscal 2025.
What was MAIA Biotechnology's earnings per share (EPS) in fiscal 2025?
MAIA Biotechnology's diluted EPS was -$0.70 for fiscal 2025 (adjusted for any later stock splits).
What was MAIA Biotechnology's revenue last quarter?
In its most recent reported quarter (2026 Q2), MAIA Biotechnology reported revenue of $0.
How many shares of MAIA Biotechnology are outstanding?
MAIA Biotechnology reported a weighted average of 60.8 million basic shares outstanding in 2026 Q2.
What is MAIA Biotechnology's market cap?
Based on its latest closing price, MAIA Biotechnology (MAIA) has a market capitalization of about $70.5M.
When does MAIA Biotechnology's fiscal year end?
MAIA Biotechnology's fiscal year end, as registered with the SEC, is December 31.
Where is MAIA Biotechnology headquartered?
MAIA Biotechnology lists its business address in Chicago, Illinois in its SEC filings.